Akeso, Inc. Enjoys Bright Prospects as Favored by the Capital Market
- 2020年04月24日 19:37:00
- テクノロジー
- JCN Newswire
- コメント
Efficient R&D Platform and Strong R&D Strength
The Company is dedicated to finding solutions to treat tumors and immunological diseases. It is generally known that it takes years to develop a new drug. However, the Company has over 20 drug development programs developed in-house though it has been established for only eight years. These programs include 12 antibodies in clinical-stage development, six bi-specific antibodies (two of which are at the clinical stage), and four antibodies with IND approvals from the Food and Drug Administration (FDA). Its product pipelines cover several major diseases, such as tumors, immunological diseases, and cardiovascular diseases. It is worth mentioning that the Company has developed all its programs in-house. In November 2015, the Company became the first China-based biotech company to out-license a fully internally discovered monoclonal antibody to a world-leading pharmaceutical company as it out-licensed its CTLA-4 monoclonal antibody drug candidate (AK107) to Merck for a total consideration of up to USD200 million.
The Company's strong R&D capability is indispensable from its end-to-end ACE Platform that possesses comprehensive, the most cutting-edge functionalities in developing therapeutic antibodies. The ACE Platform encompasses drug development and manufacturing and enables seamless technology transfer from drug discovery and CMC to manufacturing. Moreover, it holds strong internal manufacturing capacity that is compliant with GMP standards regulated by the NMPA, FDA and EMA. All drugs in the clinical stage are produced in the Company's proprietary facilities in line with GMP standards.
Prominent Advantages of Core Products, Favored by the Capital Market
The key to biopharmaceutical success lies in R&D strength and efficiency. The player who takes the lead to develop a drug and obtain approval for launch, and who can prove commercialization capabilities will gain competitive edges.
The Company has developed industry-leading drugs with the ACE Platform including its core products: PD-1/CTLA-4 bi-specific antibody (AK104) and PD-1 monoclonal antibody drug, Penpulimab (AK105). Its products also encompass AK101, a promising monoclonal antibody against autoimmune diseases, and AK102 that has high potential to become the first cardiovascular drug candidate against PCSK9 developed in China.
The Company has led the world in terms of the R&D of bi-specific antibodies. Bi-specific antibodies are deemed as a second-generation antibody therapy against tumors. With respect to the research on bi-specific antibodies, the Company possesses the unique bifunctional antibody technology, Tetrabody, making it one of the few bi-specific antibody platforms verified in both manufacturing and clinical stage. According to clinical observation, compared with the combined therapy of Nivolumab and Ipilimumab, AK104 has demonstrated better safety and efficacy. As of September 30, 2019, over 90 bi-specific antibodies were undergoing clinic trial. Nevertheless, no PD-(L)-based bi-specific antibodies had been approved for market launch. AK104 is the world's first bi-specific antibody drug that is in the clinical trial stage. It is expected that the first new drug application (NDA) of AK104 of the Company for treating cervical cancer will result in first-mover advantage.
AK105 of the Company is a monoclonal antibody currently in late-stage clinical development. PD-1 monoclonal antibody drugs are experiencing fierce competition, as six PD-1 drugs have been launched in China. Despite the extensively competitive market, AK105 is still favored for its strong efficacy and high safety. Therefore, Sino Biopharmaceutical Limited, a HK-listed pharmaceutical leader, has cooperated with the Company to jointly develop and commercialize AK105. AK105 of the Company is the only PD-1 antibody that Sino Biopharm can use to develop PD-1-based monotherapy or combination therapy, which evidences the great commercial potential of AK105. After the new drug is launched, the wide online sale channels and immense commercial capability of Sino Biopharmaceutical Limited will be utilized by the Company to maximize the commercial value of AK105.
Thanks to its strong R&D strength and commercialization capabilities, the Company has been favored by the capital market. Through Series D financing in November last year, the Company raised USD126 million in total, with the leading investor being Sino Biopharmaceutical Limited. Medical funds like Lake Bleu Capital, OrbiMed, and AIHC Capital participated in the financing. The Company's valuation reached USD836 million after Series D financing and became nearly 18 times as high as that after Series A financing of RMB330 million in just four years. Especially, Shenzhen Capital Group Co., Ltd. (SCGC), a leading venture capital firm in China that was co-founded by the Shenzhen Municipal Government and a group of private partners, participated in every series of financing. Relevant funds under K. Wah Group became a shareholder of Akeso in the series of financing before the IPO. This also means that K. Wah Group has set foot in the healthcare sector. Investment from famous capital holders reflect Akeso's bright future.
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com
【高校野球】ロボット工学投法!?芝浦工大付・村上慶多1失点完投 データ野球で初戦突破/東東京
【日本代表】33歳稲垣祥が強烈ミドル弾「立場的にも引っ張っていかなきゃ」持ち味存分に発揮
【楽天】ヤフーレ、今季8試合目で移籍後初勝利「勝ちを取れてワクワク」7回3安打1失点
【巨人】9回4連打サヨナラ勝ち!試合決めた丸佳浩「ナイスランだった」中山礼都が一塁から生還
【中日】金丸夢斗7度目の正直ならず…プロ初勝利またお預け 7回2失点もまさかのサヨナラ負け
【日本代表】95年ぶり快挙!ジャーメイン良が4発デビュー「持ち味の爆発力は出たかな」
【ヤクルト】高卒一番乗り1軍デビュー田中陽翔、代打見逃し三振「経験積んでつなげていけたら」
本上まなみ、伊東市長の卒業証書“チラ見せ”に「誠意がないなって」
【阪神】大山悠輔が2試合連続で適時二塁打 DeNA戦での休養ベンチ発進も含め9試合連続安打
【巨人】“凱旋登板”西舘勇陽5回2失点で白星ならず「追いついてもらった後…できずに悔しい」
タイタン太田光代社長「自首させたのに、書類送検の段階で名前出るのは…」所属2人オンカジ疑惑
日焼けしたポチャッコがかわいい♪東京・原宿のハワイアンカフェ“HALEIWA”にて、ポチャッココラボカフェ7/11より開催!
佐々木希が告白「多目的トイレ不倫」の夫渡部建と離婚の話し合い「すごい怖かったと思います」
「水着みたい」元NHKアナが“ピタピタ“私服ノースリ姿「妹がプレゼント…」に「センスよい」
「胸、大きくなってない?」元セクシー女優の上原亜衣、白ビキニ大胆ボディー披露「惚れてマウ」
堀江貴文氏、羽田空港混雑に「よーわからん漫画家の予言を真に受けてる人こんなにいるんか」
小澤征悦と再婚した桑子真帆アナ(34)黒い過去が流出、衝撃の過去にネット騒然
堀江貴文氏、石破首相に”不機嫌逆ギレ”された小川彩佳にひと言ツッコミ
最高にかわいい女の子集団が巻頭グラビア! 9人の豪華な清涼グラビアは必見!
再婚した旦那に不倫されてしまった飯島直子(51)衝撃的過ぎる黒歴史が発覚する事態に
ガーシー、錦織圭の元モデル妻の暴露にネット騒然「なんで結婚したんだろ?」
有村昆(44)の不倫未遂の相手とされるセクシー女優、ネットで「唯井まひろ」と噂されるも、本人は…
小澤征悦と再婚した桑子真帆アナ(34)黒い過去が流出、衝撃の過去にネット騒然
再婚した旦那に不倫されてしまった飯島直子(51)衝撃的過ぎる黒歴史が発覚する事態に
二階堂ふみが結婚!?お相手が衝撃的過ぎてネット民「マジか・・・」
日焼けしたポチャッコがかわいい♪東京・原宿のハワイアンカフェ“HALEIWA”にて、ポチャッココラボカフェ7/11より開催!
ヒカル、浮気相手とのLINE流出にドン引きの声「キモすぎる」「吐きそう」
池袋・法律事務所で男性刺殺 容疑者は50歳同僚 「以前から恨み」
【7月21日まで】最大50%分のふるなびコインがもらえる「ふるなびメガ還元祭」3つのキャンペーンと参加方法
まるで別人?浜崎あゆみのFNS歌謡祭での姿に驚きの声

【高校野球】ロボット工学投法!?芝浦工大付・村上慶多1失点完投 データ野球で初戦突破/東東京
【日本代表】33歳稲垣祥が強烈ミドル弾「立場的にも引っ張っていかなきゃ」持ち味存分に発揮
【楽天】ヤフーレ、今季8試合目で移籍後初勝利「勝ちを取れてワクワク」7回3安打1失点
【巨人】9回4連打サヨナラ勝ち!試合決めた丸佳浩「ナイスランだった」中山礼都が一塁から生還
【中日】金丸夢斗7度目の正直ならず…プロ初勝利またお預け 7回2失点もまさかのサヨナラ負け
【日本代表】95年ぶり快挙!ジャーメイン良が4発デビュー「持ち味の爆発力は出たかな」
【ヤクルト】高卒一番乗り1軍デビュー田中陽翔、代打見逃し三振「経験積んでつなげていけたら」
本上まなみ、伊東市長の卒業証書“チラ見せ”に「誠意がないなって」
【阪神】大山悠輔が2試合連続で適時二塁打 DeNA戦での休養ベンチ発進も含め9試合連続安打
【巨人】“凱旋登板”西舘勇陽5回2失点で白星ならず「追いついてもらった後…できずに悔しい」